Vijaya Diagnostic Centre / Q4-FY26

Read the quarter in context.

A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

Positive2026-05-15Back to VIJAYADIAGNOSTICCENTRE

Revenue

₹219 Cr

verified against source

Revenue YoY

26.6%

reported change

EBITDA

₹95.5 Cr

latest reported figure

Source

screener in

record provenance

Actual signal trajectory

Where this quarter sits.

source records only
EBITDA (₹ Cr)PositiveWatchNegative
2 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q3 FY26: 86 · Positive source sentiment · 2026-01-15Q3 FY26Q4 FY26: 95.5 · Positive source sentiment · 2026-05-15Q4 FY2695.586
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Quarter read

What the record says.

Vijaya Diagnostic delivered a strong Q4 FY26 with revenue of ₹219 crore (+26.6% YoY) and EBITDA margin of 43.5% (+379bps YoY), driven by 18.5% volume growth and favorable seasonality. The wellness segment and Hyderabad market (20% growth) were key contributors. PAT stood at ₹47.9 crore (+37.5% YoY). Management guided for 40%+ EBITDA margins in FY27 despite new center investments, with capex of ₹140-150 crore for 4-5 hubs and 10-12 spokes. The automated lab in Punjagutta and genomic testing are new initiatives. Risk: competitive intensity from hospital labs and online aggregators could pressure pricing and market share.

Colored figures show movement against the previous available record.

Guidance to track

  • Management expects to deliver over 40% EBITDA margin despite new center investments and technology/talent costs.
  • Includes 4-5 hubs, 10-12 spokes, and an automated lab in Punjagutta, Hyderabad.
  • Confident of double-digit growth in Pune for the full year, driven by network expansion and corporate segment.
  • Selective price increases on certain tests, similar to previous year.

Risks flagged

  • Hospital labs and online players could pressure pricing and market share, especially in new geographies.
  • Rapid expansion into Bangalore, Kolkata, and Pune may face operational challenges and slower-than-expected ramp-up.
  • High capex of ₹140-150 crore may strain cash flows if expansion opportunities exceed planned leases.

Key quotes

  • We are very confident that in next 3 to 5 years we'll be easily doubling up our revenue from where we are now.
  • We are with growth while opening new centers we'll still be delivering 40% plus EBITDA margins.
  • The denser we grow into Kolkata, in West Bengal and into Pune, this is probably going to just get better.

Research modules

Go one layer deeper.

TranscriptRisk registerPromise ledgerClaim ledgerReality check